Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SuperGen Buys U.K.'s Astex, Building Cash-Rich Oncology Play

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal brings private Astex a long-sought NASDAQ listing and beefs up cash-rich SuperGen's lackluster pipeline.

You may also be interested in...



Astex Aims To Make Cancer Drug Resistance Futile

“Using our drugs, we’re trying to facilitate the old drugs or help them work better longer,” Astex’s Lyons said. Astex, AstraZeneca and Novartis all presented data on compounds from Astex’s fragment-based drug discovery platform at the recent American Association for Cancer Research meeting in Washington, D.C.

SuperGen, Astex Management Sell Merger Strategy To Investors

After announcing a merger of the biotechs, management sought to convince investors the combination offers the best long-term value for both sides during an analyst day.

SuperGen, Astex Management Sell Merger Strategy To Investors

After announcing a merger of the biotechs, management sought to convince investors the combination offers the best long-term value for both sides during an analyst day.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072211

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel